Artificial intelligence in pharmaceutical manufacturing: Transforming sterile compounding and quality assurance
International journal of health sciences · 15.12.2025 · 9 (3) · 945-960
DOI: 10.53730/ijhs.v9n3.15834 ↗Kurz gefasst
Fachartikel in der Zeitschrift International journal of health sciences, online erschienen am 15.12.2025. Verfasst von Gowtham Nakka und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Artificial intelligence (AI) applications in sterile compounding and 503B outsourcing facilities represent a transformative approach to enhancing quality, safety, and operational throughput in pharmaceutical manufacturing. This paper examines the current state of AI implementation in sterile compounding environments, focusing on key applications including AI-driven robotics for aseptic processing, real-time quality monitoring systems, predictive analytics, and regulatory intelligence platforms. However, implementation faces significant challenges related to data integrity, system validation, and regulatory compliance under current Good Manufacturing Practices (cGMP). The FDA's evolving regulatory framework, including the recent risk-based credibility assessment guidance, establishes structured approaches for AI system validation while emphasizing the importance of context-specific performance evaluation. Key data integrity challenges include ensuring accuracy, completeness, and consistency across multiplesystems, while maintaining comprehensive audit trails. This paper presents compliance-by-design strategies that embed regulatory requirements into AI system architecture from initial development phases, addressing critical areas such as traceability, accountability, and continuous performance monitoring. Successful AI implementation requires robust data governance frameworks, risk-based validation approaches, and integrated automation architectures that span compounding, release testing, and supply chain planning. Future opportunities include advances in explainable AI, integration with continuous manufacturing technologies, and collaborative development initiatives that will accelerate industry-wide adoption while ensuring compliance .
Zitieren
APA
Nakka, G., Gupta, S., & Pereira, A. (2025). Artificial intelligence in pharmaceutical manufacturing: Transforming sterile compounding and quality assurance. International journal of health sciences, 9(3), 945-960. https://doi.org/10.53730/ijhs.v9n3.15834
Vancouver
Nakka G, Gupta S, Pereira A. Artificial intelligence in pharmaceutical manufacturing: Transforming sterile compounding and quality assurance. International journal of health sciences. 2025;9(3):945-960. doi:10.53730/ijhs.v9n3.15834
BibTeX
@article{Nakka2025,
author = {Nakka, Gowtham and Gupta, Sakshi and Pereira, Aricson},
title = {Artificial intelligence in pharmaceutical manufacturing: Transforming sterile compounding and quality assurance},
journal = {International journal of health sciences},
year = {2025},
volume = {9},
number = {3},
pages = {945--960},
doi = {10.53730/ijhs.v9n3.15834}
}
EUVIMED